Date:6/28/2010

: Key Market Trends 95 14 Global Gastrointestinal Disorder Therapeutics Market: Competitive Landscape 96 14.1 Overview 96 14.2 Competitive Profiling 96 14.3 GlaxoSmithKline, Inc 96 14.3.1 Overview 96 14.3.2 Business Description 96 14.4 AstraZeneca 97 14.4.1 Company Overview 97 14.4.2 AZD3355 98 14.5 Pfizer Incorporated 99 14.5.1 Overview 99 14.5.2 Business Description 99 14.6 Novartis Ag 100 14.6.1 Company Overview 100 14.6.2 Business Description 100 14.7 ChemoCentryx Inc. 101 14.7.1 Overview 101 14.7.2 Gastrointestinal Disease Portfolio 101 14.7.3 Crohn's Disease Product Portfolio 101 14.8 Bristol-Myers Squibb 102 14.8.1 Overview 102 14.8.2 Gastrointestinal Disease Portfolio 102 14.8.3 Crohn's Disease Product Portfolio 102 14.9 Abbott Laboratories 103 14.9.1 Overview 103 14.9.2 Gastrointestinal Disease Portfolio 103 14.9.3 Crohn's Disease Product Portfolio 103 14.10 XenoPort, Inc. 104 14.10.1 Company Overview 104 14.10.2 XP19986 104 14.11 Addex Pharmaceuticals 105 14.11.1 Company Overview 105 14.11.2 ADX10059 105 14.12 Vecta Ltd. (Vecta) 106 14.12.1 Company Overview 106 14.12.2 Vecam 106 14.13 Ironwood Pharmaceuticals and Forest Laboratories 107 14.13.1 Company Overview 107 14.13.2 IBS pipeline portfolio 108 14.14 Tioga Pharmaceuticals 109 14.14.1 Company Overview 109 14.14.2 IBS Pipeline Porfolio 109 14.15 Alimentary Health Ltd & P & G 111 14.15.1 Company Overview 111 14.15.2 IBS Pipeline Portfolio 111 14.15.3 Bifantis (Bifidobacterium infantis 35624) 111 14.16 Lexicon 112 14.16.1 Company Overview 112 14.16.2 IBS pipeline portfolio 112 14.16.3 LX-103 112 14.17 Salix Pharmaceuticals 113 14.17.1 Overview 113 14.17.2 Business Description 113 14.17.3 IBS pipeline portfolio 114 Xifaxan (Rifaximin) 114 14.17.4 Ulcerative Colitis pipe
'/>"/>

SOURCE MarketsandMarkets Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Related biology technology :

1. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
2. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
3. Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
4. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
5. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
6. New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinsons Disease
7. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
8. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
9. Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
10. SleepQuest Raises Awareness of Sleep Disorders
11. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders